OXFORD, UK — January 20, 2021 — The Native Antigen Company (now part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its new range of veterinary reagents. The company’s offering includes over 90 high-quality native and recombinant antigens, and monoclonal and polyclonal antibodies for a range of viral, bacterial, and protozoal veterinary diseases, that can be used in the development of diagnostics and vaccines.
The company’s reagents have been developed for both livestock and companion animals, such as dogs, cats and pigs, and include a range of clinically relevant pathogens, such as coronaviruses, Borrelia, Rift Valley fever virus, African swine fever virus, Toxocara, and heartworm. Suitable for a wide range of applications, these reagents can be used in research, as well as the development of immunoassays for diagnostic and vaccine R&D. The company is continuing to expand its veterinary range and is well-positioned to respond to emerging health threats.
Dr. Andy Lane, commercial director, The Native Antigen Company, said: “With a growing appreciation of One Health and the relationship between zoonotic human and animal diseases, The Native Antigen Company aims to support the development of much-needed diagnostics and vaccines to endemic and emerging veterinary pathogens. This marks the company’s first move into the veterinary reagent market, which we expect to grow rapidly over the coming years.”
For further information about The Native Antigen Company’s veterinary reagents, please visit: https://thenativeantigencompany.com/veterinary-reagents/
